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Background: Dogs with portosystemic shunts have an altered blood amino acid pro-
file, with an abnormal branched-chained amino acid (BCAA)-to-aromatic amino acid
(AAA) ratio being the most common abnormality. Different liver diseases have dis-
tinctive amino acid profiles.
Objectives: Determine the changes in plasma amino acid profiles in dogs with extra-
hepatic portosystemic shunts (EHPSS) from diagnosis to complete closure.
Animals: Ten client-owned dogs with EHPSS closed after surgical attenuation.
Methods: Prospective cohort study. Medical treatment was instituted in dogs diag-
nosed with EHPSS. At least 4 weeks later, gradual surgical attenuation was per-
formed. Three months postoperatively, EHPSS closure was confirmed by transsplenic
portal scintigraphy. Clinical signs were scored and blood was taken before institution
of medical treatment, at time of surgery, and 3 months postoperatively. At the end of
the study, the plasma amino acid profiles were analyzed in batch.
Results: The median BCAA-to-AAA ratio was extremely low (0.6) at time of diagnosis
and remained low (0.5) at time of surgery, despite the fact that median neurological
score significantly improved from 22 to 2 after starting medical treatment (P = .04).
Three months after surgical attenuation, a significantly higher BCAA-to-AAA ratio
(1.5) was observed (P < .001).
Conclusions and Clinical Importance: Medical treatment does not improve the
BCAA-to-AAA ratio in dogs with EHPSS, despite substantial clinical improvement.
Although the ratio significantly increased after EHPSS closure, it was still indicative
of moderate to severe hepatic dysfunction in all dogs.
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1 | INTRODUCTION
The liver is an important organ involved in many essential meta-
bolic functions, including metabolism and synthesis of proteins,
carbohydrates, and fats.1 Portosystemic shunts (PSS) are vascular
anomalies that connect the portal system to the systemic circula-
tion, bypassing the liver parenchyma.2 Clinical signs associated
with PSS are growth retardation, hepatic encephalopathy (HE),
gastrointestinal signs, and urinary signs secondary to the develop-
ment of ammonium urate urolithiasis.3 Gastrointestinal signs can
occur because of decreased bile production secondary to hepatic
dysfunction, leading to maldigestion and malabsorption.3 Long-
term malabsorption can cause deficiencies in proteins, fatty acids,
and vitamins, resulting in growth retardation and skin and hair
coat changes.3,4
In dogs with hepatobiliary disease, an adequate amount of
high quality protein should be provided in the diet to avoid nega-
tive nitrogen balance.5,6 It is, however, important to assure that
dogs with HE do not receive an excessive amount of protein,
which can exacerbate clinical signs.6 Blood ammonia concentra-
tions often are linked to the presence of HE but ammonia concen-
trations can be normal despite the presence of HE.7 Other
substances such as increased amounts of glutamine, glutamate,
manganese, and systemic inflammation can contribute to HE.8-10
Also a decreased ratio of branched-chain amino acids (BCAA)-to-
aromatic amino acids (AAA) can induce derangements in central
neurotransmitter function that trigger HE.11
Two experimental studies, in which a portocaval shunt was cre-
ated in adult mongrel dogs clearly showed that amino acid profiles
changed over time. The most important alterations were a signifi-
cant increase of AAAs and a significant decrease of BCAAs, changes
that were linked to the development of HE.11,12 Similarly, a recent
study that assessed blood amino acid concentrations in dogs with
congenital PSS found lower concentrations of BCAA and higher con-
centrations of AAA in dogs with PSS compared with dogs with
chronic hepatitis and healthy dogs.13 Normal BCAA-to-AAA ratios in
dogs are reported to be 3.0 to 4.0, whereas dogs with severe hepatic
insufficiency have ratios <1.5.14 In an experimental study in dogs in
which a portocaval shunt was created after partial hepatectomy, a
BCAA-enriched diet did not have a beneficial effect on the severity
of HE.15
No research has been performed to identify the effect of med-
ical or surgical treatment on the amino acid profiles in dogs with
congenital PSS receiving medical treatment and undergoing surgi-
cal attenuation. Yet, this information is important because surgical
treatment is not always performed or successful, and conse-
quently a number of dogs with congenital PSS need life-long medi-
cal treatment.
Our aim was to determine whether the plasma amino acid profile
changes after starting medical treatment and if the plasma amino acid
profile normalizes in dogs with extrahepatic PSS (EHPSS) after com-
plete EHPSS closure.
2 | MATERIALS AND METHODS
2.1 | Animals
The study was approved by the local ethical (EC2017-49) and deonto-
logical committee (2017N06), and, before inclusion of their dog, all
owners signed an informed consent. Client-owned dogs with congeni-
tal EHPSS were prospectively enrolled. Inclusion criteria were dogs
that had not yet received medical treatment (including a liver-
supportive diet) at the time of diagnosis and that would undergo sur-
gical attenuation of the EHPSS.
After confirmation of the diagnosis of EHPSS, medical treatment
was given for a minimum of 4 weeks. All dogs received a strict liver-
supportive diet (Royal Canin hepatic, Royal Canin, Zaventem, Belgium)
divided into several small meals per day. Additional medication con-
sisted of lactulose (0.5 mL/kg q8h), metronidazole (7.5-10 mg/kg
q12h) or both lactulose and metronidazole. All dogs underwent grad-
ual attenuation of the EHPSS using either an ameroid constrictor or
thin film banding, always placed as close as possible to the systemic
circulation. Postoperatively, medical treatment was continued until
the 1-month follow-up visit. In dogs that had clinical signs compatible
with PSS or dogs with fasting ammonia concentration above the
upper limit 1 month postoperatively, lactulose was continued; in all
other dogs only the liver-supportive diet was continued until the
3-month follow-up visit. Three months postoperatively, transsplenic
portal scintigraphy was performed. After ultrasound-guided injection
of 99mTc pertechnetate into the spleen, the percentage of blood
bypassing the liver (shunt fraction) was calculated. Dogs with a shunt
fraction <4.3% were considered to have a closed EHPSS.16 Dogs that
had persistent shunting were excluded from the study.
Standardized questionnaires were completed by all owners at
diagnosis, surgery, and 1 and 3 months postoperatively, and body
weight and body condition scores (BCS, on a scale of 9) were
recorded at each visit. Gastrointestinal, urinary and neurological signs
were scored, based on a published scoring system (Table 1).17
2.2 | Blood tests
At diagnosis, at the day of surgery and 1 and 3 months after surgery,
a blood sample was taken from a jugular vein. Owners were asked to
fast their dogs for 12 hours before blood sampling. On all occasions,
1 drop of fresh blood was used to immediately measure fasting
ammonia concentration using a hand-held ammonia analyzer
(PocketChem BA, A. Menarini Diagnostics; upper limit, 45 μmol/L;
detection range, 8-285 μmol/L). At diagnosis, on the day of surgery
and 3 months after surgery, blood also was collected in a 2-mL
EDTA tube and centrifuged at 3500g for 5 minutes at 2C. Obtained
plasma was aliquoted at 250 μL and stored at 80C.
At the end of the study, frozen plasma samples were sent to an
external laboratory for analysis of a targeted metabolomics amino acid
panel, measuring 22 amino acids including the AAAs (phenylalanine,
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tryptophan and tyrosine) and the BCAAs (isoleucine, leucine and
valine). All samples were spiked with stable labeled internal standards,
extracted, and subjected to protein precipitation with an organic sol-
vent. After centrifugation, an aliquot of the supernatant was diluted
and injected onto an Agilent 1290/AB Sciex QTrap 5500 liquid
chromatography-tandem mass spectrometry unit equipped with a
C18 reversed phase ultra-high performance liquid chromatography col-
umn. The mass spectrometer was operated in positive mode using
electrospray ionization. The peak areas of the individual analyte parent
ions were measured against the peak areas of the parent ions of the
corresponding internal standards in pseudo-multiple reaction monitor-
ing mode. Quantification was performed using a weighted least squares
regression analysis generated from fortified calibration standards pre-
pared immediately before each run. Liquid chromatography-tandem
mass spectrometry raw data were collected and processed using SCIEX
OS-MQ software v1.7. Data reduction was performed using Microsoft
Excel for Office 365 v.16.
Sample analyses were carried out in 96-well plates containing
2 calibration curves and 6 quality samples per plate to monitor assay
performance. Accuracy was evaluated using high-, medium-, and low-
quality controls based on historical values from TAM146 validation.
Precision was evaluated using the quality control replicates in each
sample run.
The ratio of BCAAs-to-AAAs was determined for each dog by
dividing the sum of all BCAA plasma concentrations by the sum of all
AAA plasma concentrations at all 3 sampling points.
2.3 | Statistical analyses
Statistical analyses were performed using SPSS Statistics 26 (IBM,
Armonk). Friedman 2-way analyses were performed to assess changes
in body weight and BCS over time within dogs (at diagnosis, surgery,
1 and 3 months postoperatively). Kruskal-Wallis tests were used to
evaluate the median clinical scores and fasting ammonia concentra-
tions (at diagnosis, surgery, 1 and 3 months postoperatively) and the
median plasma concentrations of the different amino acid concentra-
tions and the BCAA-to-AAA ratio at different sampling points
(at diagnosis, surgery and 3 months postoperatively). Thereafter Fried-
man 2-way analyses were performed to assess changes in clinical
scores, fasting ammonia concentrations and in plasma amino acid con-
centrations and the BCAA-to-AAA ratio over time within dogs. If sta-
tistical differences in Friedman 2-way analyses and in Kruskal-Wallis
tests were present, pairwise multiple comparison tests using
Bonferroni correction were performed. Finally, Mann-Whitney U tests
were performed to assess differences in the different plasma amino
acid concentrations between dogs <1 year of age and dogs ≥1 year of
age. Results were considered significant if P < .05.
3 | RESULTS
3.1 | Study sample
Initially, 15 dogs were enrolled. Three months postoperatively, 5 dogs
were excluded because of persistent shunting. The remaining 10 dogs
had a median age of 12.5 months (range, 3-105 months); 5 were
<1 year of age. Eight dogs had a portocaval shunt, 1 had a
portophrenic shunt and 1 dog had both a portophrenic and
a portoazygos shunt. In the latter dog, both EHPSSs were attenuated
using an ameroid constrictor during 2 separate surgeries. In that dog,
only blood samples taken at diagnosis, at time of the first surgery and
3 months after the second surgery were analyzed. Surgical attenua-
tion using an ameroid constrictor was performed in another 7 dogs
and thin film banding was used in the 2 remaining dogs. Demographic
data, clinical scores and fasting ammonia concentrations are depicted
in Table 2. Both body weight and BCS significantly increased over
time (P = .001 and P = .01, respectively). Pairwise comparisons, how-
ever, only identified a significant increase in body weight from diagno-
sis to 3 months postoperatively (P = .001) and from 1 to 3 months
postoperatively (P = .004).
Within dogs, all clinical scores (gastrointestinal, urinary, and neu-
rological scores) significantly decreased over time (P < .001, P = .02,
and P < .001, respectively). Pairwise comparisons showed a significant
decrease in gastrointestinal scores from diagnosis to 3 months post-
operatively (P < .001), and a significant decrease in neurological scores
from diagnosis to 1 month postoperatively (P = .001) and from diag-
nosis to 3 months postoperatively (P < .001).
Fasting ammonia concentrations significantly decreased over time
within dogs (P < .001). Pairwise comparisons indicated that fasting
TABLE 1 Clinical scoring system, based on a previously published scoring system17
Frequency often - occasionally - never Multiplication factor Maximal score
Gastrointestinal signs
Salivation, decreased appetite, weight loss,
diarrhea, vomiting, melena, hematochezia
2 - 1 - 0 for each gastrointestinal sign 1 for each gastrointestinal sign 14
Urinary signs
Hematuria, stranguria, dysuria, pain while urinating 2 - 1 - 0 for each urinary sign 1 for each urinary sign 8
Neurological signs
Lethargic, unresponsive, disorientation, circling
head pressing, ataxia, blindness
2 - 1 - 0 for each neurological sign 2 for each neurological sign 40
Seizure activity, comatose 3 for each neurological sign
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ammonia concentration significantly decreased from diagnosis to
1 and to 3 months postoperatively (P = .002 and P < .001, respec-
tively) and from surgery to 1 and to 3 months postoperatively (P = .02
and P = .01, respectively).
3.2 | Amino acids
Median plasma concentrations of the different amino acids at differ-
ent time points are presented in Table 3.
For the AAAs, significant decreases were found in the plasma
concentrations of phenylalanine and tyrosine within dogs from diag-
nosis to 3 months postoperatively (P = .01 and P = .003, respectively)
and from surgery to 3 months postoperatively (P < .001 and P = .001,
respectively). No significant changes were found in plasma tryptophan
concentrations within dogs (P = .67).
Regarding BCAAs, plasma valine concentrations were the only
concentrations that changed significantly within dogs, with a signifi-
cant increase from surgery to 3 months postoperatively (P = .04).
The median BCAA-to-AAA ratios at diagnosis and surgery were
0.6 (range, 0.43-0.95) and 0.5 (range, 0.32-1.07), which were both sig-
nificantly lower than the median BCAA-to-AAA ratio 3 months post-
operatively (1.5; range, 0.58-2.24; P = .004 and P < .001,
respectively). Friedman 2-way analysis determined that the BCAA-to-
AAA ratio within dogs was significantly higher 3 months postopera-
tively compared to the BCAA-to-AAA ratio at diagnosis as well as at
time of surgery (P = .004 and P = .002, respectively).
Concerning the remaining amino acids, a significant increase in
plasma concentrations of both methionine and serine were found
within dogs from diagnosis to surgery (P = .02 and P = .01, respec-
tively), these plasma concentrations, however, significantly decreased
again from surgery to 3 months postoperatively (P = .02 and P < .001,
respectively). Plasma concentrations of arginine, citrulline, and trans-
hydroxyproline significantly increased within dogs from diagnosis to
3 months postoperatively (P = .02, P = .01, and P = .02, respectively).
Finally, plasma concentrations of glutamine, histidine and proline sig-
nificantly decreased within dogs from surgery to 3 months postopera-
tively (P = .01, P = .01, and P = .04, respectively).
Aspartic acid was significantly higher at diagnosis in dogs <1 year
of age compared to older dogs. No other statistical differences
between dogs <1 year of age and older dogs were identified.
4 | DISCUSSION
Our study determined that the plasma concentrations of individual
amino acids changed differently over time. The AAAs phenylalanine
and tyrosine, but not tryptophan, were significantly higher at the time
of diagnosis and surgery compared to 3 months postoperatively. The
plasma concentration of valine, a BCAA, was significantly higher
3 months postoperatively compared to diagnosis and surgery. The
BCAA-to-AAA ratio was extremely low at the time of diagnosis (0.6)
and did not improve after a minimum of 4 weeks of medical treat-
ment. Although the BCAA-to-AAA ratio significantly increased
3 months after gradual surgical attenuation, it was, at 1.5, still indica-
tive of the presence of moderate to severe liver dysfunction.14 The
plasma concentrations of arginine, citrulline and trans-hydroxyproline
were significantly lower at time of diagnosis compared to 3 months
postoperatively, whereas the plasma concentrations of glutamine, his-
tidine, and proline were significantly lower 3 months postoperatively
compared to the time of surgery.
Both BCAAs and AAAs are considered to be key factors in the
pathogenesis of HE.20 In contrast to other amino acids, BCAAs are pri-
marily metabolized in muscle tissue,21 where they serve as precursors
of other amino acids and as an energy substrate.22 In the presence of
hyperammonemia, BCAA metabolism in muscle tissue changes and
helps to detoxify ammonia by forming glutamine.20,23 Also in brain tis-
sue, BCAAs are used as an alternative pathway to detoxify
TABLE 2 Median (range) of demographic data, clinical scores, and fasting ammonia concentrations at diagnosis, surgery, 1 and 3 months
postoperatively of dogs with closed congenital extrahepatic portosystemic shunts after surgical attenuation
Diagnosis Surgery 1 month postoperativelya 3 months postoperativelya
Body weight (kg) 3.0 (1.4-8.0) 2.9 (1.8-9.8) 3.0 (1.6-10.0) 3.3 (2.0-11.4)
Body condition score (on scale of 9) 3 (2-6) 3.5 (3-7) 3.5 (2-7) 4 (4-9)
Weeks since start medical therapy NA 6 (4-7) 11.5 (10-28) 20.5 (19-37)
Gastrointestinal score 5 (2-10) 2 (1-4) 2b (0-5) 0c (0-2)
Urinary score 0 (0-4) 0 (0-1) 0 (0-1) 0 (NA)
Neurological score 22 (2-40) 2d (0-18) 0b (0-10) 0c,e (0-12)
Fasting ammonia (μmol/L) 150 (43-256) 76 (21-high) 14.5b,f (low-32) 14c,e (low-24)
Abbreviations: EHPSS, extrahepatic portosystemic shunts; NA, not applicable.
aOnly data after the second surgery are reported of the dog with 2 single EHPSS that underwent 2 surgeries.
bSignificant difference between median concentrations at diagnosis and 1 month postoperatively.
cSignificant difference between median concentrations at diagnosis and 3 months postoperatively.
dSignificant difference between median concentrations at diagnosis and time of surgery.
eSignificant difference between median concentrations at time of surgery and 3 months postoperatively.
fSignificant difference between median concentrations at time of surgery and 1 month postoperatively.
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TABLE 3 Median plasma concentrations of different serum amino acids at different sampling points (diagnosis, surgery, 3 months
postoperatively) in dogs with closed congenital extrahepatic portosystemic shunts after surgical attenuation. Essential amino acids are depicted in










Phenylalanine 115.3 137.2 49.5b,c
(85.1-175.8) (83.3-181.0) (41.2-70.5) 51.1-75.2
Tryptophan 57.1 50.5 48.0
(41.7-109.2) (39.6-128.2) (33.4-159.5) 35.7-94.8
Tyrosine 83.1 87.8 29.0b,c
(49.9-127.3) (60.5-129.8) (21.8-44.8) 32.9-81.5
Branched-chain amino acids
Isoleucine 37.1 35.7 47.0
(22.2-79.2) (26.2-59.2) (32.3-74.4) 37.1-77.1
Leucine 74.7 71.9 98.3
(45.3-163.4) (53.6-124.4) (67.8-150.7) 61.4-187.5
Valine 101.0 87.7 133.9c
(97.0-107.0) (60.2-169.1) (83.2-202.2) 97.8-230.0
Other amino acids
Alanine 271.3 363.3 371.0
(169.1-505.2) 261.1-542.6) (278.7-612.4) 353.6-726.5
Arginine 86.8 100.8d 119.7
(47.1-99.9) (64.9-180.3) (80.3-182.1) 69.9-158.9
Asparagine 55.3 60.0 50.0
(38.7-108.5) (32.8-89.4) (31.1-68.3) 37.2-78.3
Aspartic acid 2.7 3.1 3.2
(2.1-4.8) (2.0-6.6) (2.2-4.4) NA
Citrulline 34.1 67.2 69.2
(10.7-100.8) (19.1-156.0) (33.9-126.2) 22.2-127.3
Glutamic acid 26.2 25.9 28.5
(13.5-44.2) (16.3-48.6) (11.9-44.4) 14.1-52.2
Glutamine 912.2 888.9 629.6b,c
(565.0-1171.0) (556.6-1489.7) (535.4-936.5) 557-1003.4
Glycine 190.4 226.9 215.7
(132.2-292.4) (132.2-392.2) (128.4-279.2) 145-335.3
Histidine 80.1 101.7 68.6c
(53.3-105.3) (65.5-128.4) (60.4-77.2) 67.7-95.3
Lysine 128.8 143.5 176.6
(47.0-243.0) (44.6-250.7) (82.9-244.3) 87.6-254.2
Methionine 42.8 62.5d 44.7c
(32.9-92.2) (55.4-89.0) (35.0-71.0) 51.0-83.6
Ornithine 15.0 18.8 14.8
(6.7-29.3) (10.3-26.8) (9.8-22.6) 7.3-31.2
Proline 124.6 162.7 121.0
(55.8-169.6) (94.5-263.9) (76.4-139.6) 70.5-376.7
Serine 151.2 226.2d 116.6c
(111.8-204.8) (144.3-278.0) (73.8-195.6) 59.1-222.9
(Continues)
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ammonia,24 which becomes the main route of detoxification in case
of malnutrition.25 The glutamine that is formed, however, causes
astrocyte swelling, which in turn can aggravate HE.26 Previous experi-
mental studies, in which portocaval shunts were created in adult mon-
grel dogs that subsequently developed HE, indeed found a decrease
in plasma BCAA concentrations, which might be the consequence of
increased BCAA metabolism secondary to hyperammonemia.11,12
Nevertheless, BCAA concentrations in cerebrospinal fluid remained
stable.11 Meanwhile, it was found that plasma AAA concentrations
increased, and simultaneously, AAA concentrations in cerebrospinal
fluid increased substantially.11,12 Increased concentrations of AAAs in
cerebrospinal fluid can exacerbate HE by increasing the availability
of precursors for neurotransmitters in the brain and by disturbing
brain neurotransmission by promoting the synthesis of cerebral
catecholamines and false neurotransmitters, such as phe-
nylethanolamine and octopamine.27 In a recent study in which
amino acid profiles of dogs with congenital PSS, dogs with chronic
hepatitis, and healthy dogs were analyzed, serum concentrations
of BCAAs were significantly lower whereas serum concentrations
of tyrosine and phenylalanine (both AAAs) were significantly
higher, leading to a lower BCAA-to-AAA ratio in dogs with congen-
ital PSS compared to healthy dogs and dogs with chronic hepati-
tis.13 Although both tyrosine and phenylalanine concentrations
were very high at diagnosis in our study, all BCAAs were at the
lower end of the reference range reported in dogs,18,19,28-30 which
is consistent with previous studies.11-13 Although valine signifi-
cantly increased after surgical attenuation, it remained within nor-
mal limits. This observation suggests that changes in AAAs are
more important than changes in BCAAs, both before and after
surgery.
After starting medical treatment, clinical scores improved sig-
nificantly, but, in contrast, fasting ammonia concentrations and the
BCAA-to-AAA ratio did not. Medical treatment mainly aims at
decreasing absorption of ammonia from the intestine on the one
hand and by providing a highly digestible protein source on the
other hand. This improvement was not entirely unexpected
because clinical signs are influenced by several other substances
and situations such as manganese and systemic inflammation.9,10
A previous experimental study in dogs concluded that an overall
improved nutritional state is more important in improving clinical
signs than the proportions of amino acids that are present within
the food.11 In contrast to BCAAs, AAAs typically have a very high
extraction ratio and are rapidly metabolized by the liver,31 which
can explain why AAAs significantly decreased after surgical attenu-
ation of the EHPSS. In our study, gradual attenuation devices were
used to obtain EHPSS closure. Although ameroid constrictors are
used for gradual attenuation, complete EHPSS closure can occur as
early as 10 days postoperatively.32 Thin film banding typically is
reported to cause slower EHPSS closure, which can take up to
8 weeks if the internal diameter of the vessel is decreased to
<2.5 mm.33 Although liver perfusion is normalized once the EHPSS
is completely closed, it might take longer for liver function to
completely normalize and to restore amino acid balance. Further
research is needed to verify if the BCAA-to-AAA ratio will
completely normalize in the long-term.
In our cohort of dogs, the installed medical treatment device
did not improve the overall amino acid profile. This is an important
finding, because some dogs with PSS require life-long treatment in
case of persistent shunting after surgical attenuation or if owners
prefer not to have the EHPSS treated surgically. Because the liver
plays a critical role in the metabolism of most amino acids,31 it is
important to identify which amino acid imbalances are present, in
order to try and adjust the diet to compensate for these imbalances.
Liver-supportive diets are diets specifically manufactured for dogs
with liver disease. Liver diseases, however, are very diverse, and
amino acid profiles found in dogs with different types of liver dis-
eases vary markedly.18,28 Dogs with focal liver masses have higher
plasma glutamic acid concentrations compared to age-matched
healthy dogs regardless of whether the lesions were benign or hepa-
tocellular carcinomas, and plasma glutamic acid concentrations were
not significantly different 3 to 6 months after surgical resection of
hepatocellular carcinomas.18 Dogs with superficial necrolytic derma-
titis (also called hepatocutaneous syndrome) have mean plasma
amino concentrations that are significantly lower than those of dogs
with acute and chronic hepatitis, most likely because of increased
hepatic catabolism.28 In dogs with acute and chronic hepatitis, many
plasma amino acid concentrations however are increased because of
compromised hepatic metabolism.28 The liver-supportive diet used
in our study contains 16% protein in kibble, with the main ingredi-










Threonine 76.4 103.0 138.1
(55.8-164.5) (40.1-223.9) (64.3-189.8) 147.8-444.8
Trans-hydroxyproline 13.6 16.4 22.2
(2.8-27.6) (3.9-33.3) (4.8-28.0) NA
Abbreviations: EHPSS, extrahepatic portosystemic shunts; NA, not applicable.
aOnly data after the second surgery are reported of the dog with 2 single EHPSS that underwent 2 surgeries.
bSignificant difference between median plasma concentrations at diagnosis and 3 months postoperatively.
cSignificant difference between median plasma concentrations at time of surgery and 3 months postoperatively.
dSignificant difference between median plasma concentrations at diagnosis and time of surgery.
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protein. In the canned food, 6.5% protein is present; the main ingre-
dients are corn, rice, and poultry liver. In the dry food, methionine
and lysine are supplemented; no amino acid supplements are added
to the canned food.
After at least 4 weeks of medical treatment using a liver-
supportive diet, only methionine and serine concentrations increased
significantly. Surprisingly, both amino acid concentrations decreased
again to the concentration observed initially at diagnosis, 3 months
after surgical attenuation, despite any change in diet. Both methionine
and serine have a high liver extraction ratio.31 The most likely explana-
tion for this finding is the relatively high intake of both amino acids in
the liver-supportive diet that could only be metabolized efficiently
after surgical attenuation of the EHPSS. Methionine is an essential
amino acid that is converted into S-adenosylmethionine in the liver,
and has important physiological roles such as decreasing tissue oxida-
tive stress.34 In human medicine, controversy exist as to whether
methionine supplementation is useful in patients with chronic liver
disease.35 Our findings suggest that the liver-supportive diet used
might not be ideally balanced in terms of amino acids for dogs with
portosystemic shunting. A double-blind cross-over study found that
clinical signs of HE significantly improved in dogs with PSS
that received a diet based on soy instead of meat protein.35 Yet, the
BCAA-to-AAA ratio of the soy-based diet was only 2.05 compared to
2.30 for the meat-based diet. Despite a lower BCAA-to-AAA ratio in
the food, improved HE scores in that study were attributed to the fact
that vegetable proteins are highly digestible leading to a higher
absorption of amino acids in the small intestine and subsequently less
nitrogen reaching the colon.36 Blood amino acid concentrations were
not examined in that study. The digestibility of amino acids in food is
dependent not only on the protein source, but also on the way the
food is processed and on the presence of other components in
the food. It remains to be investigated how the composition of diets
can influence blood amino acid profiles in dogs with impaired hepatic
function.37-39
Our study had some limitations. Only a small number of dogs was
included; different small dog breeds were represented and half of the
dogs were young at the time of inclusion. In dogs, it has been shown
that blood amino acid concentrations differ between small and large
breeds.40 Because only small breed dogs were included in the study,
no influences are expected based on the breed. In people, it is well
known that blood amino acid concentrations are age-specific, with
histidine, arginine, cysteine, tyrosine and taurine being semi-essential
amino acids in children because these are important in normal devel-
opment and growth.41,42 Similar age-specific blood amino acid con-
centrations would be expected in dogs. Nevertheless, no age-specific
differences were identified in our study between dogs with EHPSS
<1 year of age and those that were older.
An age- and size-matched healthy control group could have been
included to strengthen our findings. Blood amino acid concentrations
in healthy dogs however vary among studies, with all studies describ-
ing relatively wide ranges.18,19,30 In addition, differences in reported
normal values can be explained by the fact that most studies only
included a small number of apparently healthy dogs that received
different types of food, and also by the fact that amino acids were
analyzed using different laboratory techniques.
The fact that dogs were fed different foods at inclusion makes
interpretation of concentrations obtained at diagnosis difficult. Never-
theless, our study clearly showed that even if dogs were subsequently
placed on a standardized liver-supportive diet, no differences in the
amino acid profile occurred, apart from the increases in methionine
and serine concentrations. Therefore, the influence of diets the dogs
were receiving before treatment did not seem to have much impact.
In accordance with previous studies, dogs with EHPSS had a mar-
ked decreased BCAA-to-AAA ratio. Medical treatment did not influ-
ence this ratio, notwithstanding the fact that clinical signs attributable
to HE improved substantially. Despite the fact that the BCAA-to-AAA
ratio increased significantly after surgery, it still indicated moderate to
severe liver dysfunction in all dogs with closed EHPSS, suggesting that
functional recovery requires more time than does clinical recovery.
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